Latest News Year 2024 2023 2022 2021 2020 2019 2018 2017 2016 Search US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute Oct 14 2024 Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI Sep 18 2024 US FDA Grants RPD Designation to Senhwa Biosciences Silmitasertib for Pediatric Neuroblastoma Sep 13 2024 Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress. Sep 09 2024 Senhwa Biosciences receives US FDA Study May Proceed letter for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors. Aug 07 2024 Senhwa Biosciences Clinical Data Abstract of Pidnarulex Accepted for Presentation at 2024 ESMO Congress. Jul 12 2024 Senhwa Biosciences Announces IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors. Jul 11 2024 Senhwa Biosciences Announces Jason Huang, MD as New Chief Medical Officer May 13 2024 1 2 3 4 5 6 7 8